Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 6/20 | 0.44 |
| ▸ | EDNRA | P25101 | 5/20 | 0.38 |
| ▸ | EDNRB | P24530 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.37 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.37 |
| ▸ | OXTR | P30559 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5520710 | 0.89 | AGTR1 (0.45) | AGTR1EDNRAEDNRBOPRM1OPRK1 | |
| SCHEMBL4775333 | 0.84 | AGTR1 (0.51) | AGTR1EDNRAEDNRBLTB4R2ABCB11 | |
| SCHEMBL4771875 | 0.77 | EDNRA (0.59) | AGTR1EDNRAEDNRB | |
| SCHEMBL5525827 | 0.76 | EDNRA (0.54) | EDNRAEDNRB | |
| SCHEMBL4776095 | 0.74 | AGTR1 (0.51) | AGTR1EDNRALTB4R2ABCB11GP6 | |
| SCHEMBL5529478 | 0.74 | AGTR1 (0.55) | AGTR1OPRM1OPRK1LTB4R2ABCB11 | |
| SCHEMBL5525953 | 0.73 | AGTR1 (0.54) | AGTR1EDNRAOPRM1OPRK1LTB4R2 | |
| SCHEMBL4771630 | 0.73 | EDNRA (0.59) | EDNRAEDNRB | |
| SCHEMBL4766229 | 0.73 | EDNRA (0.59) | EDNRAEDNRB | |
| SCHEMBL5530777 | 0.72 | EDNRA (0.59) | AGTR1EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1741713-A2 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | Bristol-Myers Squibb Company (US) | 2007-01-10 | — | — | EP | claimed |
| US-20040127515-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2004-07-01 | — | — | US | claimed |
| US-20020143024-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2002-10-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127515-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | AGTR1 4/4885EDNRA 3/4885EDNRB 1/4885 |
| US-20020143024-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | AGTR1 4/4885EDNRA 3/4885EDNRB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.